H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 133 Citations 99,210 1,062 World Ranking 912 National Ranking 15

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Myocardial infarction
  • Heart failure

His scientific interests lie mostly in Internal medicine, Cardiology, Myocardial infarction, Heart failure and Surgery. Hazard ratio, Ejection fraction, Heart disease, Atrial fibrillation and Confidence interval are the primary areas of interest in his Internal medicine study. His Cardiology research incorporates elements of Clinical endpoint and Randomized controlled trial.

His Myocardial infarction research is multidisciplinary, incorporating perspectives in Stroke, ACE inhibitor and Risk factor. In his work, Captopril is strongly intertwined with Valsartan, which is a subfield of Heart failure. His Surgery study incorporates themes from Clinical trial, Risk of mortality, Epidemiology, Cohort study and Comorbidity.

His most cited work include:

  • ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. (5331 citations)
  • Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (2012 citations)
  • ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (1893 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Myocardial infarction and Hazard ratio. He merges Internal medicine with In patient in his research. Lars Køber studied Cardiology and Surgery that intersect with Epidemiology.

The Heart failure study combines topics in areas such as Incidence, Clinical endpoint, Randomized controlled trial, Dapagliflozin and Valsartan. His work carried out in the field of Myocardial infarction brings together such families of science as Heart disease and Risk factor. His study in Hazard ratio is interdisciplinary in nature, drawing from both Interquartile range, Cohort study, Cohort and Comorbidity.

He most often published in these fields:

  • Internal medicine (84.47%)
  • Cardiology (60.93%)
  • Heart failure (38.04%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (84.47%)
  • Cardiology (60.93%)
  • Heart failure (38.04%)

In recent papers he was focusing on the following fields of study:

Lars Køber mainly investigates Internal medicine, Cardiology, Heart failure, Hazard ratio and Ejection fraction. As part of his studies on Internal medicine, he often connects relevant areas like Dapagliflozin. His Cardiology study integrates concerns from other disciplines, such as Clinical endpoint and Interquartile range.

His work in Heart failure tackles topics such as Diabetes mellitus which are related to areas like Mace and Kidney disease. His research in Hazard ratio intersects with topics in Blood pressure and Cohort study. Lars Køber works mostly in the field of Ejection fraction, limiting it down to topics relating to Placebo and, in certain cases, Empagliflozin.

Between 2019 and 2021, his most popular works were:

  • Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. (195 citations)
  • Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes (76 citations)
  • Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure (71 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Heart failure
  • Myocardial infarction

His primary areas of investigation include Internal medicine, Heart failure, Cardiology, Ejection fraction and Hazard ratio. His Atrial fibrillation, Confidence interval and Myocardial infarction study in the realm of Internal medicine interacts with subjects such as In patient. His Heart failure research is multidisciplinary, relying on both Genome-wide association study, Cohort study, Diabetes mellitus, Electrocardiography and Mendelian inheritance.

His research integrates issues of Magnetic resonance imaging, Cardiac magnetic resonance imaging, Clinical endpoint, Fibrosis and Hyperkalemia in his study of Cardiology. His Ejection fraction study combines topics from a wide range of disciplines, such as Valsartan, Placebo, Randomized controlled trial and MEDLINE. His Hazard ratio research includes themes of Absolute risk reduction, Interquartile range, Proportional hazards model and Cohort.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Stamatis Adamopoulos;Stefan D. Anker;Volkmar Falk;Lars Køber.
European Heart Journal (2012)

10477 Citations

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

John J.V. McMurray;Stamatis Adamopoulos;Stefan D. Anker;Angelo Auricchio.
European Heart Journal (2012)

7218 Citations

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

Marc A. Pfeffer;John J.V. McMurray;Eric J. Velazquez;Jean-Lucien Rouleau.
The New England Journal of Medicine (2003)

3054 Citations

Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

Niklas Nielsen;Jørn Wetterslev;Tobias Cronberg;David Erlinge.
The New England Journal of Medicine (2013)

2396 Citations

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.

Nagesh S Anavekar;John J V McMurray;Eric J Velazquez;Scott D Solomon.
The New England Journal of Medicine (2004)

2252 Citations

A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction

Lars Køber;Christian Torp-Pedersen;Jan E. Carlsen;Henning Bagger.
The New England Journal of Medicine (1995)

2136 Citations

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients

Marcus D. Flather;Salim Yusuf;Lars Køber;Marc Pfeffer.
The Lancet (2000)

2006 Citations

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer;Brian L. Claggett;Rafael Diaz;Kenneth Dickstein.
The New England Journal of Medicine (2015)

1741 Citations

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray;Scott D. Solomon;Silvio E. Inzucchi;Lars Køber.
The New England Journal of Medicine (2019)

1545 Citations

Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction

Torp-Pedersen C;Møller M;Bloch-Thomsen Pe;Køber L.
The New England Journal of Medicine (1999)

1339 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Lars Køber

Gregory Y.H. Lip

Gregory Y.H. Lip

University of Liverpool

Publications: 488

John J.V. McMurray

John J.V. McMurray

University of Glasgow

Publications: 333

John G.F. Cleland

John G.F. Cleland

National Institutes of Health

Publications: 253

Gunnar H. Gislason

Gunnar H. Gislason

National Heart Foundation of Australia

Publications: 233

Scott D. Solomon

Scott D. Solomon

Brigham and Women's Hospital

Publications: 229

Christian Torp-Pedersen

Christian Torp-Pedersen

Aalborg University

Publications: 224

Faiez Zannad

Faiez Zannad

University of Lorraine

Publications: 223

Marco Metra

Marco Metra

University of Brescia

Publications: 213

Gerasimos Filippatos

Gerasimos Filippatos

National and Kapodistrian University of Athens

Publications: 192

Piotr Ponikowski

Piotr Ponikowski

Wrocław Medical University

Publications: 182

Aldo P. Maggioni

Aldo P. Maggioni

Heart Care Foundation, ANMCO Research Center, Florence

Publications: 181

Gregg C. Fonarow

Gregg C. Fonarow

University of California, Los Angeles

Publications: 179

Karl Swedberg

Karl Swedberg

University of Gothenburg

Publications: 174

Javed Butler

Javed Butler

University of Mississippi

Publications: 163

Dirk J. van Veldhuisen

Dirk J. van Veldhuisen

University Medical Center Groningen

Publications: 159

Something went wrong. Please try again later.